Zeynel Abidin Abidin Öztürk1, İbrahim Halil Türkbeyler1, Zeynep Demir2, Muhammet Bilici3, Yalçın Kepekçi3. 1. Department of Internal Medicine, Division of Geriatrics, Medical Faculty of Gaziantep University, Gaziantep, Turkey. 2. Department of Radiology, New York University, Center for Biomedical Imaging, New York, USA. 3. Department of Internal Medicine, Medical Faculty of Gaziantep University, Gaziantep, Turkey.
Abstract
OBJECTIVES: This study aims to evaluate the effect of blood glucose regulation on sarcopenia parameters in sarcopenic, obese, and poorly- regulated diabetic patients. PATIENTS AND METHODS: Between June 2013 and December 2013, a total of 147 patients (64 males, 83 females; mean age 70.3±6.3 years; range, 60 to 90 years) who were diagnosed with sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria were included in the study. All patients were obese with a body mass index (BMI) of >30 kg/m2 and their glycated hemoglobin (HbA1c) levels were above 8%. Sarcopenia parameters including the gait speed, muscle strength, muscle mass, and handgrip strength were assessed. After a six-month treatment period, the patients were divided into two groups according to their HbA1c levels as having <8% or >8%. Sarcopenia parameters were evaluated before and after receiving treatment. RESULTS: The mean disease duration was 16±6.2 years. Sixty patients were found to have a HbA1c level of <8% and 45 patients with a HbA1c level of ≥8% at sixth months of follow-up. In better regulated group, sarcopenia parameters such as gait speed, muscle mass, and handgrip strength improved; however, only the change in the muscle mass was found to be statistically significant (p=0.041). There was no significant change in the parameters of sarcopenia in the patient group with a HbA1c level ≥8%. A negative correlation was found between the muscle mass and HbA1c levels in good- and poorly-regulated groups (p=0.039 r:-0.327 and p=0.044 r:-0.183, respectively). CONCLUSION: Our study demonstrates that lowering HbA1c levels may have positive effects on the muscle mass even in diabetic and sarcopenic obese elderly individuals.
OBJECTIVES: This study aims to evaluate the effect of blood glucose regulation on sarcopenia parameters in sarcopenic, obese, and poorly- regulated diabetic patients. PATIENTS AND METHODS: Between June 2013 and December 2013, a total of 147 patients (64 males, 83 females; mean age 70.3±6.3 years; range, 60 to 90 years) who were diagnosed with sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria were included in the study. All patients were obese with a body mass index (BMI) of >30 kg/m2 and their glycated hemoglobin (HbA1c) levels were above 8%. Sarcopenia parameters including the gait speed, muscle strength, muscle mass, and handgrip strength were assessed. After a six-month treatment period, the patients were divided into two groups according to their HbA1c levels as having <8% or >8%. Sarcopenia parameters were evaluated before and after receiving treatment. RESULTS: The mean disease duration was 16±6.2 years. Sixty patients were found to have a HbA1c level of <8% and 45 patients with a HbA1c level of ≥8% at sixth months of follow-up. In better regulated group, sarcopenia parameters such as gait speed, muscle mass, and handgrip strength improved; however, only the change in the muscle mass was found to be statistically significant (p=0.041). There was no significant change in the parameters of sarcopenia in the patient group with a HbA1c level ≥8%. A negative correlation was found between the muscle mass and HbA1c levels in good- and poorly-regulated groups (p=0.039 r:-0.327 and p=0.044 r:-0.183, respectively). CONCLUSION: Our study demonstrates that lowering HbA1c levels may have positive effects on the muscle mass even in diabetic and sarcopenic obese elderly individuals.
Authors: J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace Journal: J Gerontol A Biol Sci Med Sci Date: 2000-04 Impact factor: 6.053
Authors: Marjolein Visser; Marco Pahor; Dennis R Taaffe; Bret H Goodpaster; Eleanor M Simonsick; Anne B Newman; Michael Nevitt; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2002-05 Impact factor: 6.053
Authors: Anne B Newman; Catherine L Haggerty; Bret Goodpaster; Tamara Harris; Steve Kritchevsky; Michael Nevitt; Toni P Miles; Marjolein Visser Journal: J Am Geriatr Soc Date: 2003-03 Impact factor: 5.562
Authors: Craig S Stump; Kevin R Short; Maureen L Bigelow; Jill M Schimke; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: Mary Elizabeth Patti; Atul J Butte; Sarah Crunkhorn; Kenneth Cusi; Rachele Berria; Sangeeta Kashyap; Yoshinori Miyazaki; Isaac Kohane; Maura Costello; Robert Saccone; Edwin J Landaker; Allison B Goldfine; Edward Mun; Ralph DeFronzo; Jean Finlayson; C Ronald Kahn; Lawrence J Mandarino Journal: Proc Natl Acad Sci U S A Date: 2003-06-27 Impact factor: 12.779
Authors: Tzyy-Guey Tseng; Chun-Kuan Lu; Yu-Han Hsiao; Shu-Chuan Pan; Chi-Jung Tai; Meng-Chih Lee Journal: Int J Environ Res Public Health Date: 2020-04-21 Impact factor: 3.390